Novavax, Inc. [NVAX] stock prices are up 2.64% to $17.11 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The NVAX shares have gain 23.54% over the last week, with a monthly amount glided 30.51%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Novavax, Inc. [NASDAQ: NVAX] stock has seen the most recent analyst activity on May 10, 2024, when JP Morgan upgraded its rating to a Neutral. Previously, BofA Securities upgraded its rating to Neutral on May 10, 2024, and elevated its price target to $12. On August 09, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $15 on the stock. TD Cowen downgraded its rating to a Market Perform and decreased its price target to $10 on April 20, 2023. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $10 on March 01, 2023. B. Riley Securities reiterated a Buy rating for this stock on January 09, 2023, and downed its price target to $37. In a note dated December 30, 2022, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $207 to $110.
The stock price of Novavax, Inc. [NVAX] has been fluctuating between $3.53 and $23.86 over the past year. Currently, Wall Street analysts expect the stock to reach $74.67 within the next 12 months. Novavax, Inc. [NASDAQ: NVAX] shares were valued at $17.11 at the most recent close of the market. An investor can expect a potential return of 336.41% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
The Novavax, Inc. [NASDAQ:NVAX] reported sales of 996.61M for trailing twelve months, representing a surge of 15.94%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.48%, and Net Profit Margin reading is -0.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is 0.53 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.68 points at the first support level, and at 16.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.67, and for the 2nd resistance point, it is at 18.24.
Ratios To Look Out For
It’s worth pointing out that Novavax, Inc. [NASDAQ:NVAX]’s Current Ratio is 0.90. On the other hand, the Quick Ratio is 0.88, and the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 2.41.
Transactions by insiders
Recent insider trading involved YOUNG JAMES F, Director, that happened on Jun 21 ’24 when 7500.0 shares were sold. Director, YOUNG JAMES F completed a deal on Jun 18 ’24 to sell 7500.0 shares. Meanwhile, President, R&D Dubovsky Filip sold 13904.0 shares on Jun 17 ’24.
